Off-Label Preclearance Process Eyed As Potential Fix For FDA's Policy Dilemma

However, FDA lacks funding to promptly respond to off-label promotion submissions on broad scale; model outlined in settlement of Amarin's Vascepa case could bolster support for third-party vetting system.